Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 1 53-1, 2003, Pages

  Nakamura, Shigefumi ^a   Averill, David B ^a   Chappell, Mark C ^a   Diz, Debra I ^a   Brosnihan, K Bridget ^a   Ferrario, Carlos M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Angiotensin receptor antagonists; Angiotensin (1 7); Hypertension; Losartan; PD 123319; Salt depletion; Spontaneously hypertensive rats

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; DEXTRO ALANINE; LOSARTAN;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HEART RATE; HOMEOSTASIS; MALE; MEAN ARTERIAL PRESSURE; MEASUREMENT; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; SODIUM DEPLETION; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION;

EID: 0037215628     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00210.2002     Document Type: Article

References (45)

1. Abbas A, Gorelik G, Carbini LA, and Scicli AG. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 30: 217-221, 1997.
2. Ardaillou R. Active fragments of angiotensin. II. Enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 6: 28-34, 1997.
3. Barber MN, Sampey DB, and Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 34: 1112-1116, 1999.
4. Benter IF, Diz DI, and Ferrario CM. Cardiovascular actions of angiotensin-(1-7). Peptides 14: 679-684, 1993.
5. Brosnihan KB, Li P, and Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523-528, 1996.
6. Brosnihan KB, Li P, Tallant EA, and Ferrario CM. Angiotensin-(1-7): A novel vasodilator of the coronary circulation. Biol Res 31: 227-234, 1998.
7. Carey RM, Howell NL, Jin XH, and Siragy HM. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 38: 1272-1277, 2001.
8. Carey RM, Wang ZQ, and Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35: 155-163, 2000.
9. Chappell MC, Diz DI, and Jacobsen DW. Pharmacological characterization of angiotensin II binding sites in the canine pancreas. Peptides 13: 313-318, 1992.
10. Chung O, Stoll M, and Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Pressure 2: 47-52, 1997.
11. Ferrario CM, Brosnihan KB, Diz DI, Jaiswal N, Khosla MC, Milsted OA, and Tallant EA. Angiotensin-(1-7): A new hormone of the angiotensin system. Hypertension 18: III-126-III-133, 1991.
12. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, and Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
13. Freeman EJ, Chisolm GM, Ferrario CM, and Tallant EA. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104-108, 1996.
14. 3H]norepinephrine from rat atria. Hypertension 24: 457-460, 1994.
15. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355, 1998.
16. Handa RK, Harding JW, and Simasko SM. Characterization and function of the bovine kidney epithelial angiotensin receptor type 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands. J Pharmacol Exp Ther 291: 1242-1249, 1999.
17. Harding JW, Wright JW, Swanson GN, Hanesworth JM, and Krebs LT. AT4 receptors: Specificity and distribution. Kidney Int 46: 1510-1512, 1994.
18. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, and Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor, Nature 377: 748-750, 1995.
19. Iyer SN, Averill DB, Chappell MC, Yamada K, Jones AG, and Ferrario CM. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 36: 417-422, 2000.
20. Iyer SN, Chappell MC, Averill DB, Diz DI, and Ferrario CM. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699-705, 1998.
21. Iyer SN, Ferrario CM, and Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 31: 356-361, 1998.
22. Iyer SN, Yamada K, Diz DI, Ferrario CM, and Chappell MC. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. J Cardiovasc Pharmacol 36: 109-117, 2000.
23. Jaiswal N, Diz DI, Tallant EA, Khosla MC, and Ferrario CM. The non-peptide angiotensin II antagonist DuP 753 is a potent stimulus for prostacyclin synthesis. Am J Hypertens 4: 228-233, 1991.
24. Li P, Chappell MC, Ferrario CM, and Brosnihan KB. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29: 394-400, 1997.
25. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 281: 1065-1070, 1997.
26. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, and Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 99: 1926-1935, 1997.
27. Luscher TF, Raij L, and Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 9: 157-163, 1987.
28. 2 receptor ligands CGP 42112B and PD123319 in the sodium-depleted rat. Eur J Pharmacol 249: 85-93, 1993.
29. 2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 259: 27-36, 1994.
30. Michel JB, Guettier C, Reade R, Sayah S, Corvol P, and Menard J. Immunologic approaches to blockade of the renin-angiotensin system: A review. Am Heart J 117: 756-768, 1989.
31. Nakamoto H, Ferrario CM, Fuller SB, Robaczewski DL, Winicov E, and Dean RH. Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. Hypertension 25: 796802, 1995.
32. Nishioka T, Morris M, Li P, Ganten D, Ferrario CM, and Callahan MF. Depressor role of angiotensin AT2 receptors in the (mRen-2)27 transgenic rat. Am J Hypertens 11: 357-362, 1998.
33. Paula RD, Lima CV, Britto RR, Campagnole-Santos MJ, Khosla MC, and Santos RAS. Potentiation of the hypotensive effect of bradykinin by angiotensin-(1-7)-related peptides. Peptides 20: 493-500, 1999.
34. Santos RAS, Campagnole-Santos MJ, Baracho NCV, Fontes MAP, Silva LCS, Neves LAA, Oliveira DR, Caligiorne SM, Rodrigues ARV, Gropen C Jr, Carvalho WS, Silva ACSE, and Khosla MC. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): Evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull 35: 293-398, 1994.
35. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, and Brosnihan KB. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Peptides 15: 919-926, 1994.
36. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100: 264-269, 1997.
37. 2α formation in conscious rats. Am J Physiol Regul Integr Comp Physiol 273: R1103-R1107, 1997.
38. Siragy HM and Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 33: 1237-1242, 1999.
39. Siragy HM, de Gasparo M, and Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 35: 1074-1077, 2000.
40. Tallant EA, Diz DI, and Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension 34: 950-957, 1999.
41. Tallant EA, Landrum MH, and Gallagher PE. Attenuation of human breast and lung cancer cell growth by angiotensin-(1-7) (Abstract). FASEB J 15: A778, 2001.
42. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, and Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104: 925-935, 1999.
43. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, and Zhu YZ. Angiotensin receptors. J Hypertens 14: S95-S103, 1996.
44. 1-receptor antagonists, EXP 3174. Br J Pharmacol 107: 873-880, 1992.
45. Widdop RE, Gardiner SM, Kemp PA, and Bennett T. Central administration of PD 123319 or EXP-3174 inhibits effects of angiotensin II. Am J Physiol Heart Circ Physiol 264: H117-H125, 1993.